Short Interest in bluebird bio, Inc. (NASDAQ:BLUE) Grows By 9.6%

bluebird bio, Inc. (NASDAQ:BLUE) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 32,620,000 shares, a growth of 9.6% from the March 31st total of 29,750,000 shares. Based on an average trading volume of 8,500,000 shares, the short-interest ratio is currently 3.8 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BLUE shares. HSBC decreased their price objective on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research report on Tuesday, March 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $6.00 target price on shares of bluebird bio in a research note on Wednesday, March 27th. StockNews.com raised bluebird bio to a “sell” rating in a research note on Thursday, March 28th. Wells Fargo & Company lowered their price objective on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 27th. Finally, William Blair reissued a “market perform” rating on shares of bluebird bio in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, bluebird bio currently has an average rating of “Hold” and a consensus target price of $5.74.

bluebird bio Trading Up 1.8 %

BLUE opened at $0.94 on Tuesday. The company has a market cap of $102.78 million, a price-to-earnings ratio of -1.25 and a beta of 0.74. The company’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.95. bluebird bio has a 1-year low of $0.88 and a 1-year high of $5.53.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently made changes to their positions in the business. Aigen Investment Management LP bought a new position in bluebird bio during the 3rd quarter valued at $34,000. Sequoia Financial Advisors LLC bought a new position in shares of bluebird bio during the fourth quarter valued at about $37,000. Dynamic Technology Lab Private Ltd bought a new position in shares of bluebird bio during the fourth quarter valued at about $37,000. Johnson Investment Counsel Inc. boosted its holdings in bluebird bio by 111.1% during the fourth quarter. Johnson Investment Counsel Inc. now owns 27,889 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 14,680 shares during the last quarter. Finally, Enterprise Bank & Trust Co bought a new stake in bluebird bio in the 1st quarter worth about $38,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.